Value-based care in behavioral health ties payment to the results of care rather than its volume. The behavioral health field's standard measures, such as the PHQ-9 and GAD-7, track symptom severity, while contracts also depend on how patients function, engage with treatment, and use care. Cognitive difficulties often outlast mood symptoms, and in one 3-year primary care study, cognitive problems were present 44% of the time during remission from depression.
Because cognition shapes whether patients can follow a treatment plan, it connects symptom measures to the functional and utilization outcomes contracts reward. Standardized cognitive assessment measures attention, memory, processing speed, and executive function in a consistent, repeatable way, and used alongside symptom scales and direct measures of daily functioning, it gives behavioral health organizations a fuller view of risk and outcomes across a population.
For executives and clinical leaders accountable for behavioral health performance in value-based arrangements, the sections below cover why measurement has slowed progress, what symptom measures miss, and how cognitive data supports quality, risk, and cost performance.
Article Highlights
Improvement in behavioral health rarely follows a single path. A patient may report fewer symptoms without regaining daily function, while another may avoid hospitalization with little change in symptom scores. Outcomes also unfold over months, across settings, and depend heavily on engagement, which makes them harder to attribute and compare than completed visits.
Routine measurement is also far from universal. Fewer than 20% of behavioral health practitioners use measurement-based care, in which standardized measures guide treatment decisions. Even the collaborative care model, which embeds behavioral healthcare in primary care settings and treats to measurable targets, typically sets those targets on symptom scales.
Policy has started to respond. The Centers for Medicare & Medicaid Services (CMS) Innovation in Behavioral Health (IBH) Model, running in Michigan, New York, and South Carolina through 2032, places behavioral health practices at the center of integrated care and pairs performance-based payments from 2028 with investments in screening, assessment, and interoperability.
Industry groups are moving in the same direction, and in October 2026 the Behavioral Health Outcomes Consortium launched a standardized outcomes framework covering symptom reduction, daily functioning, and post-discharge status, with a first pilot phase planned for 2027.
As more payment depends on performance, consistent and usable measurement becomes a prerequisite for behavioral health organizations in value-based arrangements.
Symptom scales are the backbone of behavioral health measurement. The PHQ-9 and GAD-7 assess depression and anxiety severity, and the HEDIS depression measures build on the PHQ-9 to evaluate:
These measures track whether symptoms improve, and functional recovery can lag behind. A meta-analysis of cognitive impairment in depression found moderate deficits in executive function and attention that persisted after mood symptoms remitted.
In a longitudinal study of major depressive disorder, visual memory and executive function performance during the acute episode was associated with social functioning after remission, while symptom severity was not.
Symptom scales show whether a patient feels better, and direct measures of daily functioning show how that patient is managing work, relationships, and self-care. Cognitive performance helps explain the distance between the two, and outcomes measurement in value-based arrangements benefits from all three.
Many behavioral health conditions involve changes in attention, memory, processing speed, or executive function. These changes affect whether patients remember instructions, manage medications, plan daily tasks, and stay engaged in behavioral healthcare. The domains affected, and how much they matter clinically, vary by condition and by patient.
| Condition or population | What the evidence links cognition to |
|---|---|
| Major depressive disorder | Executive function and memory performance during an episode was associated with social functioning after remission. |
| Attention-deficit/hyperactivity disorder | Adults with ADHD show working memory deficits, which may interfere with organization and follow-through. |
| Schizophrenia and related serious mental illness | Cognitive performance predicts later community functioning. |
| Substance use disorders | Memory, attention, executive function, and decision-making may be affected, with patterns varying by substance and recovery stage. |
| Older adults with severe psychiatric illness | Cognitive impairment is associated with higher mental healthcare costs. |
Symptom scores and clinical impressions can leave these difficulties unmeasured. Standardized cognitive assessment captures them in a form that can be compared across patients and over time, and clinicians interpret results alongside history, symptom measures, and functional assessment to decide whether further evaluation is warranted.
Value-based arrangements reward organizations for managing quality and cost across populations. In behavioral health, much of that performance depends on engagement: whether patients attend follow-up, take medications as prescribed, and stay in treatment long enough to benefit. Cognitive difficulties can affect each of these, so measuring them gives care teams and leadership information that symptom scales leave out. The value comes from how the organization acts on it.
Behavioral health performance already appears across value-based programs. HEDIS includes measures such as follow-up after hospitalization for mental illness, initiation and engagement of substance use disorder treatment, and adherence to antipsychotic medications for individuals with schizophrenia. For the 2026 Star Ratings, CMS returned the Improving or Maintaining Mental Health measure, which carries a weight of 1 in 2026 and 3 beginning in 2027.
The HEDIS measures depend partly on whether patients keep appointments, follow a medication plan, and remain in treatment, which cognitive difficulties can make harder. Cognitive assessment supports the quality improvement work behind these measures. When a care team knows a patient has difficulty with attention or memory, it can simplify instructions, confirm understanding, or involve a support person with the patient's permission.
At the population level, standardized cognitive data supports risk stratification. An organization can examine whether patients with identified cognitive difficulties miss more follow-up visits or need more care coordination, direct support toward those groups, and track whether engagement and outcomes change. Framing lower scores as a prompt for support keeps the approach clinically appropriate and avoids reducing patients to a risk label.
Medicare Advantage risk scores are built from documented diagnoses, and CMS audits whether submitted diagnoses are supported by the medical record. Behavioral health conditions such as schizophrenia, bipolar disorder, and substance use disorders map to hierarchical condition categories, so documentation quality shapes how accurately a population's complexity is represented.
A cognitive assessment result identifies concerns that warrant clinical evaluation. In older patients with behavioral health conditions, that evaluation may confirm a comorbid condition such as dementia, which the current CMS-HCC model assigns to separate categories by stage. The value lies in documentation that reflects the complexity a care team is actually managing, backed by the clinical record.
Across behavioral health conditions, cognitive difficulties are associated with the outcomes that drive total cost of care. In a nationally representative U.S. sample, adults with schizophrenia who reported cognitive limitations had annual healthcare costs of $18,478 compared with $11,689 for those without, along with higher odds of hospitalization and emergency department visits.
The same pattern appears in treatment engagement. A systematic review of 46 studies in addiction treatment found medium-sized associations between general cognition and treatment adherence, and in late-life depression, deficits in planning and organization were associated with poorer antidepressant response.
Consider a patient in mental health treatment who struggles to follow a medication plan. A symptom score shows persistent distress, a review of daily routines shows missed doses and appointments, and cognitive assessment points to difficulty with attention or working memory that warrants further evaluation. The care team simplifies instructions, changes follow-up methods, or coordinates additional support, and reassessment alongside utilization data shows whether the approach is working.
For organizations carrying risk, these associations make cognitive status a higher priority in care management and utilization review. The broader case for earlier detection in risk-bearing models is covered in how cognitive assessment tools support value-based care.
Measurement-based care works when clinicians use results to guide decisions. In a randomized clinical trial in a Norwegian psychiatric outpatient clinic, clients whose therapists received routine feedback on psychotherapy outcomes were 2.5 times more likely to improve than those in usual care, and the advantage grew as the clinic gained experience with the system.
Cognitive assessment adds a different kind of measure to that practice, one based on performance and repeatable over time. Its effect on treatment outcomes depends on how results are used, which makes clear definitions important. Results are defensible when an organization defines:
With these in place, change in cognitive performance becomes an outcome an organization can track alongside symptom scores across its population.
The value of cognitive assessment depends on implementation, and implementation starts with purpose. An integrated behavioral health program may use it to identify patients who need further evaluation, understand variation within a high-utilization population, or track change during treatment, and that purpose determines who is assessed and when.
| Implementation area | Key program considerations |
|---|---|
| Population approach | Who receives the assessment, what triggers it, and when reassessment occurs |
| Workflow ownership | Who administers the assessment, reviews the result, documents it, and responds |
| Capacity | Clinician time for review, care coordination for follow-up, and referral pathways |
| Data integration | Where results appear in the health record and how they feed population-level reporting |
| Action rules | Which findings trigger clinical evaluation, workflow support, or escalation |
| Success measures | Completion and follow-up rates, and change in engagement, function, and quality measures |
Results also need to reach the systems teams already use. Placement in the electronic health record, population-level reporting, patient accessibility, and implementation support across sites determine whether assessment results can inform care coordination, quality reporting, and population analysis.
Timing matters as much as placement. The assessment has to reach patients within an existing care setting early enough to shape the care plan, delivering the right service at the right time and place.
Value-based care in behavioral health will keep asking organizations to show what changed, for whom, and at what cost. Symptom measures and direct assessment of daily functioning remain central to that work, and cognitive assessment adds information that helps explain why a program that looks successful on symptom scores can still leave patients struggling to manage their care.
Written by Andrea Welsh, LPN, CHPC
Andrea Welsh, LPN, CHPC, is a nurse and medical writer with clinical experience in geriatric, primary care, and behavioral health settings. She has managed quality and compliance programs supporting value-based care in community health centers and holds the Certified in Healthcare Privacy Compliance (CHPC) credential. She speaks at healthcare conferences on data literacy and clinical documentation.